Anilides
Aobchem 1-Bromo-2-(propan-2-yloxy)naphthalene | ≥97% | CAS 791088-70-5 | C13H13BrO | 500mg
1-Bromo-2-(propan-2-yloxy)naphthalene | ≥97% | CAS 791088-70-5 | C13H13BrO | 500mg
Aobchem 2-Bromo-6-(difluoromethoxy)naphthalene | ≥97% | CAS 244103-47-7 | C11H7BrF2O | 1g
2-Bromo-6-(difluoromethoxy)naphthalene | ≥97% | CAS 244103-47-7 | C11H7BrF2O | 1g
Aobchem 2 3-Dimethylacetanilide | ≥97% | CAS 134-98-5 | C10H13NO | 500mg
2 3-Dimethylacetanilide | ≥97% | CAS 134-98-5 | C10H13NO | 500mg
Aobchem 1-Bromo-4-(phenylmethoxy)-naphthalene | ≥97% | CAS 138865-41-5 | C17H13BrO | 25g
1-Bromo-4-(phenylmethoxy)-naphthalene | ≥97% | CAS 138865-41-5 | C17H13BrO | 25g
Aobchem 1-Bromo-4-(difluoromethoxy)naphthalene | ≥97% | CAS 1261783-62-3 | C11H7BrF2O | 1g
1-Bromo-4-(difluoromethoxy)naphthalene | ≥97% | CAS 1261783-62-3 | C11H7BrF2O | 1g
Aobchem 2 3-Dimethylacetanilide | ≥97% | CAS 134-98-5 | C10H13NO | 10g
2 3-Dimethylacetanilide | ≥97% | CAS 134-98-5 | C10H13NO | 10g
Cambridge Isotope Laboratories Resveratrol (4-hydroxyphenyl-13C6 99%) 1 mg
Resveratrol (4-hydroxyphenyl-13C6 99%) 1 mg
Apexbio Technology LLC Leflunomide 75706-12-6 10mM (in 1mL DMSO)
Leflunomide (CAS 75706-12-6) is a small-molecule agonist targeting the aryl hydrocarbon receptor (AHR) pathway It is designed to modulate AHR signaling thereby enhancing regulatory T cell (Treg) numbers altering inflammatory cytokine profiles and influencing immune responses Leflunomide exerts its biological activity primarily through metabolic conversion to its active metabolite Teriflunomide (A771726) which mediates immunosuppressive effects It enhances IL-10 production and suppresses IL-17 and IL-23 secretion In cell-based studies leflunomide demonstrates anti-proliferative efficacy in human medullary thyroid carcinoma cells (MTC-TT) with IC50 values ranging from approximately 30 to 50 M depending on specific assay conditions Based on these pharmacological properties leflunomide holds research potential in ischemia-reperfusion renal injury sepsis-induced intestinal oxidative stress and tumor proliferation inhibition models